Clinical Trial Update: Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating setmelanotide for obesity in patients with pseudohypoparathyroidism type 1a; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Pseudohypoparathyroidism Type 1a

Drugs mentioned

• Setmelanotide (setmelanotide)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Pseudohypoparathyroidism Type 1a, Obesity | Phase 2 | Status: NOT_YET_RECRUITING